Panbela Therapeutics Inc.
PBLA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$53.89K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $53,889.00 |
|---|---|
| Enterprise Value | $3.11 Million |
| Earnings per Share | $-232429.55 |
| Beta | 1.88 |
| Outstanding Shares | 4,854,861 |
Return
| Return on Equity | 153.59% |
|---|---|
| Return on Assets | -539.96% |
| Return on Invested Capital | 295.89% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.07 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.03 |
| Debt to Equity | -0.18 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-2640.00
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-2640.00
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Panbela Therapeutics Inc
6 employees
CEO: Michael Cullen
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients ...